Last reviewed · How we verify
Alcohol 30%
At a glance
| Generic name | Alcohol 30% |
|---|---|
| Sponsor | Tanta University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Virtual Reality (VR) NATURE - Alcohol Use Disorder (AUD) (NA)
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency (PHASE2)
- Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder (PHASE2)
- Flexibility, Alcohol Misuse, and Excitation (NA)
- Tritordeum-based Foods for IBS Symptoms (NA)
- Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD) (NA)
- Antiplaque Efficacy and Patient Reported Outcome of Chlorohexidine, Cetylpyridinium Chloride, and Essential Oil Mouthwashes in Orthodontic Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alcohol 30% CI brief — competitive landscape report
- Alcohol 30% updates RSS · CI watch RSS
- Tanta University portfolio CI